Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 4/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9770695 | 0.78 | ALDH1A1 (0.37) | KCNA5PARP1PARP10PARP11PDE7A | |
| SCHEMBL30791259 | 0.76 | CD44 (0.35) | PDK2PARP1ALDH1A1KDM1A | |
| SCHEMBL21132394 | 0.76 | PDK2 (0.35) | PDK2PARP10PARP11PDE7AHDAC4 | |
| SCHEMBL24597113 | 0.76 | PDE7A (0.33) | PDE7AKDM1A | |
| SCHEMBL29428514 | 0.76 | PDK2 (0.35) | PDK2PARP10PARP11PDE7AHDAC4 | |
| SCHEMBL23356013 | 0.76 | CD44 (0.35) | PDK2PARP1ALDH1A1KDM1A | |
| SCHEMBL22827158 | 0.76 | PDK2 (0.40) | PDK2OPRM1KRASSOS1ALDH1A1 | |
| SCHEMBL23995720 | 0.76 | CA2 (0.36) | KRASSOS1PDE7AALDH1A1HDAC4 | |
| SCHEMBL17571273 | 0.74 | CYP11B1 (0.39) | KCNA5PDK2OPRM1PARP1PARP10 | |
| SCHEMBL19654764 | 0.74 | CYP11B1 (0.39) | KCNA5PDK2OPRM1PARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| EP-4148056-A1 | SOS1 INHIBITOR CONTAINING PHOSPHORUS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-03-15 | — | — | EP | disclosed |
| EP-3728254-B1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AG (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022268209-A1 | DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF | 四川汇宇制药股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022148442-A1 | 6-SUBSTITUTED PHOSPHORYL QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-07-14 | — | — | WO | disclosed |
| WO-2021074227-A1 | 2-METHYL-AZA-QUINAZOLINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021027943-A1 | PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| WO-2021000933-A1 | PYRIMIDINONE COMPOUNDS AS CHYMASE INHIBITORS AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2021-01-07 | — | — | WO | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | KCNA5 3230/4885PDK2 3428/4885OPRM1 747/4885 |
| US-20230029385-A1 | 2-METHYL-AZA-QUINAZOLINES | AZI2, DNMT1, TPMT | KCNA5 3239/4885PDK2 1215/4885OPRM1 4707/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | KCNA5 4571/4885PDK2 3782/4885OPRM1 572/4885 |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | KCNA5 2912/4885PDK2 3532/4885OPRM1 1129/4885 |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | KCNA5 3289/4885PDK2 3438/4885OPRM1 789/4885 |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | KCNA5 2960/4885PDK2 3519/4885OPRM1 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.